Home › Bayer announces FDA acceptance of BAY 81-8973 BLA for treatment of hemophilia A
 

Keywords :   


Bayer announces FDA acceptance of BAY 81-8973 BLA for treatment of hemophilia A

2015-03-04 21:03:00| Chemicals - Topix.net

Bayer HealthCare today announced that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for BAY 81-8973, a recombinant Factor VIII compound. Bayer is seeking FDA approval of the investigational compound, proposed trade name Kovaltry, for the treatment of hemophilia A in children and adults.

Tags: of treatment acceptance bay

Category:Chemicals

Latest from this category

All news
04.11Registration Open for 2025 Waterborne Symposium
04.11ROSS Ribbon Blenders Provide Safe, Efficient Bulk Blending
04.11U.S. Green Building Council Announces 2024 Leadership Award Recipients
04.11ASTM International Publishes New Standards for FT4 Powder Rheometer Procedures
04.11Nippon Paint Marine Uses Biomimetics to Unlock Next Generation in Hull Coatings
04.11AkzoNobels Yacht Brands Lead the Way in Digital Training and Support
02.11Weekly Recap: Nippon Paint, AkzoNobel, PPG Top This Weeks Stories
01.11BASF TotalEnergies Petrochemicals Receives United Way Champions of Hope Award
Chemicals »
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 7
05.11Tropical Storm Rafael Public Advisory Number 7
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 7
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
More »